Savara (NASDAQ:SVRA - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Savara to post earnings of ($0.12) per share for the quarter.
Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The company had revenue of $0.27 million during the quarter. On average, analysts expect Savara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Savara Trading Up 4.3 %
SVRA traded up $0.14 during midday trading on Friday, hitting $3.40. 706,717 shares of the company were exchanged, compared to its average volume of 1,299,663. The firm's 50 day moving average price is $2.83 and its 200-day moving average price is $3.06. Savara has a 1-year low of $2.26 and a 1-year high of $5.31. The firm has a market capitalization of $586.95 million, a P/E ratio of -7.91 and a beta of 0.52. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Savara in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.83.
Get Our Latest Stock Analysis on SVRA
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
